Enhanced transient receptor potential channel-mediated Ca2+ influx in the cells with phospholipase C-δ1 overexpression: its possible role in coronary artery spasm

Fundam Clin Pharmacol. 2017 Aug;31(4):383-391. doi: 10.1111/fcp.12269. Epub 2017 Feb 16.

Abstract

We reported that coronary spasm was induced in the transgenic mice with the increased phospholipase C (PLC)-δ1 activity. We investigated the effect of enhanced PLC-δ1 on Ca2+ influx and its underlying mechanisms. We used human embryonic kidney (HEK)-293 and coronary arteries smooth muscle cells (CASMC). Intracellular free Ca2+ concentration ([Ca2+ ]i ; nm) was measured by fura-2, and Ca2+ influx was evaluated by the increase in [Ca2+ ]i after addition of extracellular Ca2+ . Acetylcholine (ACh) was used to induce Ca2+ influx. ACh-induced peak Ca2+ influx was 19 ± 3 in control HEK-293 cells and 71 ± 8 in the cells with PLC-δ1 overexpression (P < 0.05 between two groups). Nifedipine partially suppressed this Ca2+ influx, whereas either 2-APB or knockdown of classical transient receptor potential channel 6 (TRPC6) blocked this Ca2+ influx. In the human CASMC, ACh-induced peak Ca2+ influx was 29 ± 6 in the control and was increased to 45 ± 16 by PLC-δ1 overexpression (P < 0.05). Like HEK-293 cells, pretreatment with nifedipine partially suppressed Ca2+ influx, whereas either 2-APB or knockdown of TRPC6 blocked it. ACh-induced Ca2+ influx was enhanced by PLC-δ1 overexpression, and was blocked partially by nifedipine and completely by 2-APB. TRPC-mediated Ca2+ influx may be related to the enhanced Ca2+ influx in PLC-δ1 overexpression.

Keywords: Intracellular Ca2+ concentration; PLC-δ1; coronary spasm; transient receptor potential channel 6.

MeSH terms

  • Calcium / metabolism*
  • Calcium Channel Blockers / pharmacology
  • Coronary Vasospasm / enzymology*
  • Coronary Vasospasm / genetics
  • Coronary Vessels / drug effects
  • Coronary Vessels / enzymology*
  • Gene Expression Regulation, Enzymologic*
  • HEK293 Cells
  • Humans
  • Myocytes, Smooth Muscle / drug effects
  • Myocytes, Smooth Muscle / enzymology
  • Phospholipase C delta / biosynthesis*
  • Phospholipase C delta / genetics
  • TRPC6 Cation Channel / antagonists & inhibitors
  • TRPC6 Cation Channel / metabolism*

Substances

  • Calcium Channel Blockers
  • TRPC6 Cation Channel
  • TRPC6 protein, human
  • Phospholipase C delta
  • Calcium